Intraperitoneal vs IV Chemotherapy in Ovarian Cancer: How Do They Compare?

A trial compared two intraperitoneal chemotherapy regimens and an intravenous regimen for newly diagnosed advanced ovarian carcinoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

ConclusionLaparoscopic approach to isolated relapse of ovarian cancer is feasible and safe, with fast recovery
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
ConclusionIt is important to maintain a suspicion for GI tract metastasis in breast cancer patients who present with abdominal mass or GI symptoms, as this aids in prompt institution of accurate and appropriate management.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
CONCLUSIONS: Platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy. PMID: 31604666 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Abstract Recently, an increasing number of studies have reported that dysregulation of long noncoding RNAs (lncRNAs) plays an important role in cancer initiation and progression, including in epithelial ovarian carcinoma (EOC). However, little is known about the detailed biological functions of the lncRNA small nucleolar RNA host gene 22 (SNHG22) during the progression of EOC. Here, we found that SNHG22 was significantly increased in EOC tissues and was significantly associated with a low level of differentiation. Forced SNHG22 expression promoted chemotherapy resistance in EOC cells. Knockdown of SNHG22 expressio...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
This report describes a patient whose presenting complaints were “Physical examination showed that the pancreas was occupied for one month.” He initially was diagnosed with stage IV PC based on conventional imaging and pathologic assessment. He had a known germline BRCA 2 mutation, which exhibited a good response to PARP inhibitor therapy. Diagnosis: Through the biopsy histopathological examination, imaging examination, and genetic testing, the patient was diagnosed as metastatic PC with BRCA2 mutation. Interventions: He received gemcitabine and albumin-bound paclitaxel chemotherapy from March 15, 2017 to...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
AbstractBackgroundTumor Treating Fields (TTFields) are a non-invasive, antimitotic therapy delivered to the tumor via transducer arrays applied to the skin at tumor site. The only TTFields-related adverse event (AE) reported in clinical trials was localized dermatitis beneath the arrays. The safety of TTFields has also been investigated in glioblastoma, non-small-cell lung cancer (NSCLC), mesothelioma, pancreatic and ovarian cancer. This meta-analysis reported AEs in clinical studies with TTFields torso delivery.Methods192 patients from 4 pilot studies were included in the analysis: EF-15 (n  = 41, advanced N...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. Pol J Pathol. 2019;70(2):115-126 Authors: Kowalik A, Zalewski K, Kopczyński J, Siołek M, Lech M, Hińcza K, Kalisz J, Chrapek M, Zięba S, Furmańczyk J, Jedliński M, Chłopek M, Misiek M, Góźdź S Abstract Ovarian cancer (OC) is the most lethal among gynecologic malignancies worldwide. Unfortunately, in around 70% of cases cancer is diagnosed in late stages (III-IV) which decreases the 5-year survival rate to 25%. The standard of care in ovarian cancer is debulking s...
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
This review article provides an in ‐depth information on current treatment strategies and available clinical trials for ovarian cancer. Systematic review of strategies for enhancing the therapeutic response in ovarian carcinoma summarizing the recent developments in translational and clinical research. AbstractOf all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced ‐stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early‐stage detection is one of the major challenges linked...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinom a;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Gra...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: The distribution of disease at the time of first recurrence varied with the choice of primary treatment. Compared to patients treated with PDS, patients who underwent NACT-IDS experienced recurrence more often in the same locations as the original disease. PMID: 31521322 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Ovarian Cancer | Ovaries